{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:40:28Z","timestamp":1789681228784,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.nmd.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T05:47:07Z","timestamp":1619243227000},"page":"656-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Marked reduction in paralytic attacks in a patient with Andersen-Tawil syndrome switched from acetazolamide to dichlorphenamide"],"prefix":"10.1016","volume":"31","author":[{"given":"Anirudh","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Iyadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Roggenbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.04.001_bib0001","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1651-2227.1971.tb06990.x","article-title":"Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome?","volume":"60","author":"Andersen","year":"1971","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.nmd.2021.04.001_bib0002","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ana.410350313","article-title":"Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features","volume":"35","author":"Tawil","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.04.001_bib0004","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.nmd.2018.03.006","article-title":"Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands","volume":"28","author":"Stunnenberg","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.04.001_bib0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mus.26009","article-title":"Review of the diagnosis and treatment of periodic paralysis","volume":"57","author":"Statland","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.04.001_bib0006","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1212\/NXG.0000000000000284","article-title":"Variable penetrance of Andersen-Tawil syndrome in a family with a rare missense KCNJ2 mutation","volume":"4","author":"Deeb","year":"2018","journal-title":"Neurol Genet"},{"key":"10.1016\/j.nmd.2021.04.001_bib0007","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.nmd.2016.11.006","article-title":"Intrafamilial phenotypic variability in Andersen-Tawil syndrome: a diagnostic challenge in a potentially treatable condition","volume":"27","author":"Ardissone","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.04.001_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0092-8674(01)00342-7","article-title":"Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome","volume":"105","author":"Plaster","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2021.04.001_bib0009","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1212\/WNL.0000000000000239","article-title":"A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1","volume":"82","author":"Kokunai","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.04.001_bib0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1172\/JCI15183","article-title":"Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome)","volume":"110","author":"Tristani-Firouzi","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2021.04.001_bib0011","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1016\/j.ydbio.2018.02.012","article-title":"Kir2.1 is important for efficient BMP signaling in mammalian face development","volume":"444","author":"Belus","year":"2018","journal-title":"Dev Biol"},{"key":"10.1016\/j.nmd.2021.04.001_bib0012","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/jbmr.3474","article-title":"Osteogenic and chondrogenic master genes expression is dependent on the Kir2.1 potassium channel through the bone morphogenetic protein pathway","volume":"33","author":"Pini","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2021.04.001_bib0013","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/mcne.1997.0655","article-title":"Ontogeny of gene expression of Kir channel subunits in the rat","volume":"10","author":"Karschin","year":"1997","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.nmd.2021.04.001_bib0014","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nurt.2007.01.005","article-title":"Management and treatment of Andersen-Tawil syndrome (ATS)","volume":"4","author":"Sansone","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2021.04.001_bib0015","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/europace\/eut160","article-title":"Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation","volume":"15","author":"Delannoy","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.nmd.2021.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","article-title":"Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis","volume":"86","author":"Sansone","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.04.001_bib0017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1531-8249(200001)47:1<46::AID-ANA9>3.0.CO;2-H","article-title":"Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on periodic paralysis","volume":"47","author":"Tawil","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.04.001_bib0018","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e31823a0cb6","article-title":"Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype","volume":"77","author":"Matthews","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.04.001_bib0019","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1096\/fj.03-0722fje","article-title":"Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats","volume":"18","author":"Tricarico","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.nmd.2021.04.001_bib0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.59.3.466","article-title":"Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome","volume":"59","author":"Junker","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.04.001_bib0021","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/01.wnl.0000178888.03767.74","article-title":"Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation","volume":"65","author":"Davies","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.04.001_bib0022","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.hrthm.2015.03.032","article-title":"Imipramine for incessant ventricular arrhythmias in 2 unrelated patients with Andersen-Tawil syndrome","volume":"12","author":"Bigelow","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.nmd.2021.04.001_bib0023","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/mus.26705","article-title":"Clinical and neurophysiological variability in Andersen-Tawil syndrome","volume":"60","author":"Kokubun","year":"2019","journal-title":"Muscle Nerve"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621000985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621000985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:36Z","timestamp":1760775096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0960896621000985"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.04.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marked reduction in paralytic attacks in a patient with Andersen-Tawil syndrome switched from acetazolamide to dichlorphenamide","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}